8-K: Dyadic International Announces Second Quarter 2024 Financial Results and Highlights Progress in Multiple Sectors

Dyadic International reported its second quarter 2024 financial results, highlighting progress in alternative proteins, animal health, and human health sectors, along with a decrease in revenue and net loss compared to the same period last year.

Summary

• Dyadic International announced its financial results for the second quarter of 2024, showing a decrease in revenue to $386,000 from $837,000 in the same period last year due to the winding down of several large research collaborations.
• The company's net loss for the quarter was $2,045,000, or $(0.07) per share, compared to a net loss of $2,153,000, or $(0.07) per share, in the second quarter of 2023.
• Cash and investment grade securities totaled $10.1 million as of June 30, 2024, up from $7.3 million at the end of 2023.
• Dyadic has entered into a development and commercialization partnership with Proliant Health and Biologicals for animal-free recombinant albumin products, receiving an initial payment of $500,000 in July 2024.
• A joint development agreement was established with a top 10 global dairy company for non-animal alpha-lactalbumin.
• The company's C1-produced adjuvanted H5 avian influenza vaccine candidate showed a strong immune response in animal studies.
• Dyadic is focusing on enhancing its Dapibus platform for non-pharmaceutical applications in food, nutrition, and wellness.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in partnerships and technology, the financial results show a significant decrease in revenue and continued losses. The sentiment is neutral to slightly negative due to the financial performance.

Positives

• Dyadic's cash position improved significantly, reaching $10.1 million.
• The partnership with Proliant Health and Biologicals provides a clear path to revenue generation with an initial payment of $500,000.
• The joint development agreement with a major dairy company validates the potential of Dyadic's technology in the food sector.
• The strong immune response observed in animal studies for the avian influenza vaccine candidate is a promising development.
• The successful expression of H1N1 influenza antigen demonstrates the effectiveness of Dyadic's platform for vaccine development.
• The company is actively sampling recombinant alpha-lactalbumin and lactoferrin to multiple interested parties.
• The development of three enzymes with potential for use in multiple industries is progressing.

Negatives

• Revenue decreased significantly to $386,000 compared to $837,000 in the same quarter last year.
• The company continues to operate at a loss, with a net loss of $2,045,000 for the quarter.
• General and administrative expenses increased to $1,608,000 compared to $1,403,000 in the same period last year.
• The decrease in revenue is attributed to the winding down of several large research collaborations.

Risks

• The company has a history of net losses, which may continue.
• Market and regulatory acceptance of Dyadic's technologies is not guaranteed.
• The company faces competition from alternative technologies.
• The success of nonclinical studies and clinical trials is uncertain.
• Dyadic relies on third parties, which introduces risk.
• Changes in global economic and financial conditions could impact the company.
• Intellectual property risks could affect the company's competitive advantage.

Future Outlook

Dyadic is focused on enhancing the Dapibus platform for non-pharmaceutical applications and targeting multiple offtakes for single products across various business segments. The company anticipates the launch of the first recombinant human serum albumin product in the first half of 2025.

Management Comments

• Mark Emalfarb, President and CEO of Dyadic, stated that the company saw the positive impact of its business strategy, focusing on near-term non-pharmaceutical applications and midto long-term applications in animal and human health.
• Joe Hazelton, Dyadic's Chief Operating Officer, commented that the company has refined its business development strategy to concentrate on areas where its technologies can achieve commercialization more quickly.
• Mr. Emalfarb also mentioned that the company remains focused on enhancing the Dapibus platform for non-pharmaceutical uses and targeting multiple offtakes for a single product.

Industry Context

This announcement reflects a broader trend in the biotechnology industry towards developing innovative protein production platforms for various applications, including alternative proteins, animal health, and human health. The focus on non-pharmaceutical applications aligns with the growing demand for sustainable and cost-effective solutions in food, nutrition, and wellness.

Comparison to Industry Standards

• Dyadic's focus on microbial protein production platforms is comparable to companies like Amyris and Ginkgo Bioworks, which also utilize synthetic biology for various applications.
• The development of recombinant albumin and alpha-lactalbumin aligns with the trend of using non-animal sources for these proteins, similar to efforts by companies like Perfect Day and Clara Foods in the alternative protein space.
• The strong immune response observed in Dyadic's avian influenza vaccine candidate is a positive sign, but further clinical trials are needed to compare its efficacy to existing vaccines from companies like Sanofi and GSK.
• The decrease in revenue and continued losses are not uncommon for early-stage biotech companies, but Dyadic needs to demonstrate a clear path to profitability, similar to the challenges faced by other companies in the sector.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and continued losses, but encouraged by the progress in partnerships and technology.
• Employees may be affected by the company's financial performance, but motivated by the advancements in research and development.
• Customers and partners may be interested in the potential of Dyadic's technologies and products.
• Suppliers and creditors may be monitoring the company's financial stability.

Next Steps

• Dyadic will continue to enhance the Dapibus platform for non-pharmaceutical applications.
• The company plans to deliver a production strain to its partner for verification related to the non-animal dairy enzymes agreement.
• Dyadic expects to begin sampling DNASE-1 in the third quarter.
• Product samples of recombinant transferrin are expected to be available in the fourth quarter.
• The company anticipates the launch of the first recombinant human serum albumin product in the first half of 2025.

Key Dates

Keywords

biotechnology, recombinant proteins, vaccines, alternative proteins, animal health, human health, C1 platform, Dapibus platform, avian influenza, ferritin nanoparticle, alpha-lactalbumin, albumin, enzymes